Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Pharmaceutical cannabis producer, Creso Pharma has entered a buyout agreement posited from Canada’s PharmaCielo for AU$122 million
  • PharmaCielo is a parent to Colombia’s biggest cannabis producer and will integrate its supply chain with Creso
  • Production and distribution of Creso’s human and animal-focused wellness products will move to the well-established Colombian and Canadian facilities

Share prices in Creso Pharma spiked up 32 per cent this morning after the company announced a buy out with a leading Canadian cannabis company.

The pharmaceutical cannabis producer has had a positive past few months in business, and now moving to belong to PharmaCielo, for the price of AU$122 million.

Creso Pharma CEO Miri Halperin Wernli says the forces joined between the two companies will bring a unique skill set to the growing market.

“The quality and scale of PharmaCielo’s cultivation and oil extraction operations in Colombia complements our focus on meeting global demand for the highest quality cannabis-derived therapeutic, nutraceutical and animal health products through increased access to the necessary quality and volume of oil production,” she said.

PharmaCielo is the Canadian parent company to Colombia-based PharmaCielo Colombia Holdings S.A.S, the country’s biggest producer in the market with fully licensed medicinal cannabis oil products already selling off shelves.

The 100 per cent buyout was valued at a price of 63 cents per share. Buyer PharmaCielo’s current market cap in the TSX Venture Exchange is CAD$675 million.

Creso and PharmaCielo’s supply chains will be integrated, bringing extra value to the buyers through Creso’s rang of animal-focused cannabis products.

Production and distribution of Creso Pharma’s products will be moved to the highly established facilities in Canada and Colombia.

PharmaCielo CEO David Attard says the industry should prepare for the powerhouse forming in the buyout.

“Upon closing of the transaction the combined company will quadruple our global footprint with presence in more than a dozen countries spanning North and Latin America, Switzerland, Europe, the Middle East, Australia and New Zealan,.” he said.

Attard said the already popular Colombian products offered by the company will hit new markets as part of the deal, effective immediately.

Share prices in CPH closed yesterday at 42.50 cents. This morning they briefly spiked to 57 cents, but are now settled at 54.5 cents a piece. The company’s market cap remains at $57.10 million.

CPH by the numbers
More From The Market Herald
Emeco (ASX:EHL) - CEO & Managing Director, Ian Testrow

" Emeco (ASX:EHL) recaps a solid FY22 performance with growth across all segments

Mining equipment solutions provider Emeco (ASX:EHL) increases revenue by 22 per cent to $754 million for…
Memphasys (ASX:MEM) - Managing Director & CEO, Alison Coutts

" Memphasys (ASX:MEM) launches $3.36m capital raising for Felix System commercialisation

Reproduction biotechnology and bio-separations company Memphasys (ASX:MEM) has launched a $3.36 million capital raising.
The Market Herald Video

" PharmAust (ASX:PAA) sees “significant progress” in dog cancer trials

Biotech company PharmAust (ASX:PAA) has reported "significant progress" on its canine cancer.
XTEK (ASX:XTE) - CEO, Scott Basham

" XTEK’s (ASX:XTE) HighCom receives $2.7m US Government order

XTEK's (ASX:XTE) HighCom Armor Solutions business has received a $2.7 million order from a US Federal…